News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Oppenheimer Holdings Inc.

Form 4 CalciMedica, Inc. For: Jun 27 Filed by: Roberts Eric W

Form 8-K CalciMedica, Inc. For: Jun 27

Form 4 CalciMedica, Inc. For: May 17 Filed by: Geffken Daniel E.

Form 10-Q CalciMedica, Inc. For: Mar 31

Form 8-K CalciMedica, Inc. For: May 13

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}